Head to Head Analysis: Immatics (NASDAQ:IMTX) & Exscientia (NASDAQ:EXAI)

Exscientia (NASDAQ:EXAI) and Immatics (NASDAQ:IMTX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, valuation and risk.

Analyst Ratings

This is a breakdown of current ratings and price targets for Exscientia and Immatics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exscientia	0	4	0	0	2.00
Immatics	0	0	4	1	3.20

Exscientia presently has a consensus target price of $7.00, indicating a potential upside of 44.63%. Immatics has a consensus target price of $16.67, indicating a potential upside of 100.32%. Given Immatics’ stronger consensus rating and higher probable upside, analysts clearly believe Immatics is more favorable than Exscientia.

Insider and Institutional Ownership

41.6% of Exscientia shares are owned by institutional investors. Comparatively, 64.4% of Immatics shares are owned by institutional investors. 16.4% of Exscientia shares are owned by company insiders. Comparatively, 3.3% of Immatics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Risk and Volatility

Exscientia has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500. Comparatively, Immatics has a beta of 0.78, suggesting that its share price is 22% less volatile than the S&P 500.

Valuation and Earnings

This table compares Exscientia and Immatics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exscientia	$25.60 million	24.72	-$181.56 million	($1.51)	-3.21
Immatics	$58.44 million	16.99	-$104.98 million	($0.66)	-12.61

Immatics has higher revenue and earnings than Exscientia. Immatics is trading at a lower price-to-earnings ratio than Exscientia, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Exscientia and Immatics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Exscientia	-882.09%	-49.10%	-33.13%
Immatics	-47.94%	-15.90%	-9.38%

Summary

Immatics beats Exscientia on 11 of the 15 factors compared between the two stocks.

About Exscientia

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.